AWP Reform Reporting Requirements Need Clear Definition, PhRMA Says
Executive Summary
The Centers for Medicare & Medicaid Services should clearly define reporting requirements for manufacturers associated with payment reform for Part B drugs, the Pharmaceutical Research & Manufacturers of America said
You may also be interested in...
AWP Reform Will Include Manufacturer Price Reporting, CMS Predicts
Pharmaceutical manufacturers should prepare to adopt a new market price reporting system to replace the current AWP methodology used for Medicare Part B reimbursement, CMS' Center for Medicare Management Director Thomas Grissom said Nov. 13
AWP Reform Will Include Manufacturer Price Reporting, CMS Predicts
Pharmaceutical manufacturers should prepare to adopt a new market price reporting system to replace the current AWP methodology used for Medicare Part B reimbursement, CMS' Center for Medicare Management Director Thomas Grissom said Nov. 13
CMS Expected To Delay AWP Regulation; Medicare Conferees Want Credit
The Centers for Medicare & Medicaid Services is expected to hold off on issuing a final regulation reforming the AWP reimbursement methodology to allow Medicare conferees the chance to complete work on the issue